The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Targeted Drugs for Allergic Diseases Market Research Report 2025
Synopsis
Anaphylaxis is an inappropriate reaction of the immune system to normal harmless substances. It generally has a rapid onset, strong reaction, and rapid subsidence. It has obvious genetic tendencies and individual differences. Currently, the prevalence of allergic diseases is increasing rapidly worldwide, affecting approximately 25% of the global population.
Biological targeted drugs mainly reduce the inflammatory response and activity of immune cells by binding to targets such as specific regulatory factors in the type 2 immune pathway; small molecule targeted drugs include JAK inhibitors and TYK2 inhibitors, which work by blocking the JAK/STAT pathway. Immunomodulatory effects. Compared with traditional anti-allergic drugs, targeted drugs have better efficacy in severe or drug-resistant patients, and the drugs themselves are safer, and have gradually become the mainstream trend in the development of anti-allergic drugs.
The global Targeted Drugs for Allergic Diseases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Targeted Drugs for Allergic Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Targeted Drugs for Allergic Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Targeted Drugs for Allergic Diseases in Atopic Dermatitis is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Targeted Drugs for Allergic Diseases include Sanofi, Novartis, GSK, Amgen, AstraZeneca, Biosion, Pfizer, UCB and Otsuka Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Allergic Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Allergic Diseases.
Report Scope
The Targeted Drugs for Allergic Diseases market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for Allergic Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for Allergic Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Novartis
GSK
Amgen
AstraZeneca
Biosion
Pfizer
UCB
Otsuka Pharmaceutical
Roche
Keymed Biosciences
Mabpharm
Genrix Bio
Dragon Boat Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Sunshine Guojian
Qyuns Therapeutics
Segment by Type
IL-4R
TSLP
IL-5
JAK
IgE
IL-33
Others
Segment by Application
Atopic Dermatitis
Asthma
Chronic Sinusitis with Nasal Polyps
Chronic Obstructive Pulmonary Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for Allergic Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Anaphylaxis is an inappropriate reaction of the immune system to normal harmless substances. It generally has a rapid onset, strong reaction, and rapid subsidence. It has obvious genetic tendencies and individual differences. Currently, the prevalence of allergic diseases is increasing rapidly worldwide, affecting approximately 25% of the global population.
Biological targeted drugs mainly reduce the inflammatory response and activity of immune cells by binding to targets such as specific regulatory factors in the type 2 immune pathway; small molecule targeted drugs include JAK inhibitors and TYK2 inhibitors, which work by blocking the JAK/STAT pathway. Immunomodulatory effects. Compared with traditional anti-allergic drugs, targeted drugs have better efficacy in severe or drug-resistant patients, and the drugs themselves are safer, and have gradually become the mainstream trend in the development of anti-allergic drugs.
The global Targeted Drugs for Allergic Diseases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Targeted Drugs for Allergic Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Targeted Drugs for Allergic Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Targeted Drugs for Allergic Diseases in Atopic Dermatitis is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Targeted Drugs for Allergic Diseases include Sanofi, Novartis, GSK, Amgen, AstraZeneca, Biosion, Pfizer, UCB and Otsuka Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Allergic Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Allergic Diseases.
Report Scope
The Targeted Drugs for Allergic Diseases market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for Allergic Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for Allergic Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Novartis
GSK
Amgen
AstraZeneca
Biosion
Pfizer
UCB
Otsuka Pharmaceutical
Roche
Keymed Biosciences
Mabpharm
Genrix Bio
Dragon Boat Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Sunshine Guojian
Qyuns Therapeutics
Segment by Type
IL-4R
TSLP
IL-5
JAK
IgE
IL-33
Others
Segment by Application
Atopic Dermatitis
Asthma
Chronic Sinusitis with Nasal Polyps
Chronic Obstructive Pulmonary Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for Allergic Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drugs for Allergic Diseases Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 IL-4R
1.2.3 TSLP
1.2.4 IL-5
1.2.5 JAK
1.2.6 IgE
1.2.7 IL-33
1.2.8 Others
1.3 Market by Application
1.3.1 Global Targeted Drugs for Allergic Diseases Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Atopic Dermatitis
1.3.3 Asthma
1.3.4 Chronic Sinusitis with Nasal Polyps
1.3.5 Chronic Obstructive Pulmonary Disease
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drugs for Allergic Diseases Market Perspective (2019-2030)
2.2 Targeted Drugs for Allergic Diseases Growth Trends by Region
2.2.1 Global Targeted Drugs for Allergic Diseases Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Targeted Drugs for Allergic Diseases Historic Market Size by Region (2019-2024)
2.2.3 Targeted Drugs for Allergic Diseases Forecasted Market Size by Region (2025-2030)
2.3 Targeted Drugs for Allergic Diseases Market Dynamics
2.3.1 Targeted Drugs for Allergic Diseases Industry Trends
2.3.2 Targeted Drugs for Allergic Diseases Market Drivers
2.3.3 Targeted Drugs for Allergic Diseases Market Challenges
2.3.4 Targeted Drugs for Allergic Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drugs for Allergic Diseases Players by Revenue
3.1.1 Global Top Targeted Drugs for Allergic Diseases Players by Revenue (2019-2024)
3.1.2 Global Targeted Drugs for Allergic Diseases Revenue Market Share by Players (2019-2024)
3.2 Global Targeted Drugs for Allergic Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Targeted Drugs for Allergic Diseases Revenue
3.4 Global Targeted Drugs for Allergic Diseases Market Concentration Ratio
3.4.1 Global Targeted Drugs for Allergic Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Allergic Diseases Revenue in 2023
3.5 Targeted Drugs for Allergic Diseases Key Players Head office and Area Served
3.6 Key Players Targeted Drugs for Allergic Diseases Product Solution and Service
3.7 Date of Enter into Targeted Drugs for Allergic Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drugs for Allergic Diseases Breakdown Data by Type
4.1 Global Targeted Drugs for Allergic Diseases Historic Market Size by Type (2019-2024)
4.2 Global Targeted Drugs for Allergic Diseases Forecasted Market Size by Type (2025-2030)
5 Targeted Drugs for Allergic Diseases Breakdown Data by Application
5.1 Global Targeted Drugs for Allergic Diseases Historic Market Size by Application (2019-2024)
5.2 Global Targeted Drugs for Allergic Diseases Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Targeted Drugs for Allergic Diseases Market Size (2019-2030)
6.2 North America Targeted Drugs for Allergic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Targeted Drugs for Allergic Diseases Market Size by Country (2019-2024)
6.4 North America Targeted Drugs for Allergic Diseases Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drugs for Allergic Diseases Market Size (2019-2030)
7.2 Europe Targeted Drugs for Allergic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Targeted Drugs for Allergic Diseases Market Size by Country (2019-2024)
7.4 Europe Targeted Drugs for Allergic Diseases Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for Allergic Diseases Market Size (2019-2030)
8.2 Asia-Pacific Targeted Drugs for Allergic Diseases Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Targeted Drugs for Allergic Diseases Market Size by Region (2019-2024)
8.4 Asia-Pacific Targeted Drugs for Allergic Diseases Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drugs for Allergic Diseases Market Size (2019-2030)
9.2 Latin America Targeted Drugs for Allergic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Targeted Drugs for Allergic Diseases Market Size by Country (2019-2024)
9.4 Latin America Targeted Drugs for Allergic Diseases Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for Allergic Diseases Market Size (2019-2030)
10.2 Middle East & Africa Targeted Drugs for Allergic Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Targeted Drugs for Allergic Diseases Market Size by Country (2019-2024)
10.4 Middle East & Africa Targeted Drugs for Allergic Diseases Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Targeted Drugs for Allergic Diseases Introduction
11.1.4 Sanofi Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.1.5 Sanofi Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Targeted Drugs for Allergic Diseases Introduction
11.2.4 Novartis Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 GSK
11.3.1 GSK Company Detail
11.3.2 GSK Business Overview
11.3.3 GSK Targeted Drugs for Allergic Diseases Introduction
11.3.4 GSK Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.3.5 GSK Recent Development
11.4 Amgen
11.4.1 Amgen Company Detail
11.4.2 Amgen Business Overview
11.4.3 Amgen Targeted Drugs for Allergic Diseases Introduction
11.4.4 Amgen Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.4.5 Amgen Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Targeted Drugs for Allergic Diseases Introduction
11.5.4 AstraZeneca Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.5.5 AstraZeneca Recent Development
11.6 Biosion
11.6.1 Biosion Company Detail
11.6.2 Biosion Business Overview
11.6.3 Biosion Targeted Drugs for Allergic Diseases Introduction
11.6.4 Biosion Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.6.5 Biosion Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Targeted Drugs for Allergic Diseases Introduction
11.7.4 Pfizer Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 UCB
11.8.1 UCB Company Detail
11.8.2 UCB Business Overview
11.8.3 UCB Targeted Drugs for Allergic Diseases Introduction
11.8.4 UCB Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.8.5 UCB Recent Development
11.9 Otsuka Pharmaceutical
11.9.1 Otsuka Pharmaceutical Company Detail
11.9.2 Otsuka Pharmaceutical Business Overview
11.9.3 Otsuka Pharmaceutical Targeted Drugs for Allergic Diseases Introduction
11.9.4 Otsuka Pharmaceutical Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.9.5 Otsuka Pharmaceutical Recent Development
11.10 Roche
11.10.1 Roche Company Detail
11.10.2 Roche Business Overview
11.10.3 Roche Targeted Drugs for Allergic Diseases Introduction
11.10.4 Roche Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.10.5 Roche Recent Development
11.11 Keymed Biosciences
11.11.1 Keymed Biosciences Company Detail
11.11.2 Keymed Biosciences Business Overview
11.11.3 Keymed Biosciences Targeted Drugs for Allergic Diseases Introduction
11.11.4 Keymed Biosciences Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.11.5 Keymed Biosciences Recent Development
11.12 Mabpharm
11.12.1 Mabpharm Company Detail
11.12.2 Mabpharm Business Overview
11.12.3 Mabpharm Targeted Drugs for Allergic Diseases Introduction
11.12.4 Mabpharm Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.12.5 Mabpharm Recent Development
11.13 Genrix Bio
11.13.1 Genrix Bio Company Detail
11.13.2 Genrix Bio Business Overview
11.13.3 Genrix Bio Targeted Drugs for Allergic Diseases Introduction
11.13.4 Genrix Bio Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.13.5 Genrix Bio Recent Development
11.14 Dragon Boat Pharmaceutical
11.14.1 Dragon Boat Pharmaceutical Company Detail
11.14.2 Dragon Boat Pharmaceutical Business Overview
11.14.3 Dragon Boat Pharmaceutical Targeted Drugs for Allergic Diseases Introduction
11.14.4 Dragon Boat Pharmaceutical Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.14.5 Dragon Boat Pharmaceutical Recent Development
11.15 Jiangsu Hengrui Pharmaceuticals
11.15.1 Jiangsu Hengrui Pharmaceuticals Company Detail
11.15.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.15.3 Jiangsu Hengrui Pharmaceuticals Targeted Drugs for Allergic Diseases Introduction
11.15.4 Jiangsu Hengrui Pharmaceuticals Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.15.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.16 Sunshine Guojian
11.16.1 Sunshine Guojian Company Detail
11.16.2 Sunshine Guojian Business Overview
11.16.3 Sunshine Guojian Targeted Drugs for Allergic Diseases Introduction
11.16.4 Sunshine Guojian Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.16.5 Sunshine Guojian Recent Development
11.17 Qyuns Therapeutics
11.17.1 Qyuns Therapeutics Company Detail
11.17.2 Qyuns Therapeutics Business Overview
11.17.3 Qyuns Therapeutics Targeted Drugs for Allergic Diseases Introduction
11.17.4 Qyuns Therapeutics Revenue in Targeted Drugs for Allergic Diseases Business (2019-2024)
11.17.5 Qyuns Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
